common.study.topics.clinical

Combined Vaginal Misoprostol and Perivascular Vasopressin

common.study.values.description

Combined Vaginal Misoprostol and Perivascular Vasopressin

Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal. Additionally, Misoprostol has been looked at as an additional method to decrease operative blood loss given its ability to increase uterine muscle tone, which therefore constricts the amount of blood flow to the uterus.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Standard

20 units diluted in 100mL of Normal Saline injected laparoscopic needle

Drug - Standard-vaginal misoprostol

20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy

common.study.values.clinical-trial-id

NCT03815344

participant.views.study.view.id

bqxLRa